Expression and clinical significance of PKD1 and PKD2 in colorectal cancer
Objective To investigate the expression and clinical significance of PKD1 and PKD2 in colorectal cancer.Methods Cancer tissues and corresponding para-cancer tissues of 90 colorectal cancer patients admitted to the Second Forestry Hospital of Heilongjiang Province from January 2019 to December 2020 were collected.The expression of PKD1 and PKD2 was detected by immunohistochemical staining,and the relationship between PKD1 and PKD2 expression and clinicopathological features of colorectal cancer was analyzed.Survival curve was plotted by Kaplan-Meire method.Cox risk proportional regression model was used to analyze the prognostic factors of colorectal cancer.Results The positive rate of PKD1 in colorectal cancer tissues was 72.2%(65/90),higher than 31.1%(28/90)in adjacent tissues,the difference was statistically significant(P<0.05).The positive rate of PKD2 was 66.7%(60/90),higher than that of para-cancer tissues[33.3%(30/90)],the difference was statistically significant(P<0.05).The expressions of PKD1 and PKD2 were correlated with differentiation degree,TNM stage,invasion depth and lymph node metastasis(P<0.05).Kaplan-Meier analysis showed that the median overall survival(OS)of PKD1-negative patients was 34.0 months(31.5-36.0 months),which was significantly higher than that of positive patients,and the difference was statistically significant(P<0.05).The median OS of PKD2-negative patients was 33.0 months(25.6-36.2 months),which was significantly higher than that of positive patients,and the difference was statistically significant(P<0.05).Multivariate Cox proportional regression analysis showed that differentiation degree,TNM stage,lymph node metastasis,PKD1 expression and PDK2 expression were independent factors affecting OS in colorectal cancer patients(P<0.05).Conclusion PKD1 and PKD2 are highly expressed in colorectal cancer tissues,and positive expression of PKD1 and PKD2 can be used as an independent factor to evaluate the poor prognosis of patients with colorectal cancer.